Abstract
In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL). In group I, seven of 18 patients developed FL (after 10/108 courses); in group II, seven of 22 patients (7/98 courses) (P = NS). Median hospitalization duration and costs were not different. RhG-CSF was 6.6 times more expensive per course than CAB. In conclusion, prophylactic CAB has similar efficacy to rhG-CSF in this setting, and is more cost-effective.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Amphotericin B / economics
-
Amphotericin B / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Breast Neoplasms / drug therapy*
-
Ciprofloxacin / economics
-
Ciprofloxacin / therapeutic use*
-
Costs and Cost Analysis
-
Cyclophosphamide / administration & dosage
-
Drug Therapy, Combination
-
Epirubicin / administration & dosage
-
Female
-
Fever / complications
-
Fever / prevention & control
-
Fluorouracil / administration & dosage
-
Granulocyte Colony-Stimulating Factor / economics
-
Granulocyte Colony-Stimulating Factor / therapeutic use*
-
Humans
-
Length of Stay / economics
-
Leukopenia / chemically induced
-
Leukopenia / prevention & control*
-
Methotrexate / administration & dosage
-
Middle Aged
-
Neoplasm Metastasis
-
Netherlands
-
Prospective Studies
-
Recombinant Proteins / economics
-
Recombinant Proteins / therapeutic use
Substances
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor
-
Epirubicin
-
Ciprofloxacin
-
Amphotericin B
-
Cyclophosphamide
-
Fluorouracil
-
Methotrexate